Neue Entwicklungen in der perioperativen (Radio-)Chemotherapie des lokal fortgeschrittenen Rektumkarzinoms

Zusammenfassung

Die neoadjuvante 5-Fluorouracil-basierte Radiochemotherapie stellt einen Standard in der präoperativen Therapie des lokal fortgeschrittenen Rektumkarzinoms dar. In der folgenden Übersicht sollen aktuelle Daten zu einer Modifikation bzw. Intensivierung der 5-FU-basierten Radiochemotherapie vorgestellt werden. Des Weiteren wird die Rolle der Induktionschemotherapie sowie die Rolle der adjuvanten Chemotherapie nach stattgehabter neoadjuvanter Radiochemotherpaie und Tumorresektion kritisch diskutiert.

Summary

5-fluorouracil-based chemoradiotherapy represents a standard neoadjuvant treatment for patients with locally advanced rectal cancer. This review discusses recent data on the modification and intensification of 5-fluorouracil based chemoradiotherapy. Moreover, the role of induction chemotherapy as well as the role of adjuvant chemotherapy after neoadjuvant chemoradiotherapy and tumor resection is critically discussed.

Schlüsselwörter

Adjuvante Chemotherapie - Bevacizumab - Cetuximab - Chemoradiotherapie - Induktionschemotherapie - Oxaliplatin - Rektumkarzinom

Keywords

Adjuvant chemotherapy - bevacizumab - cetuximab - chemoradiotherapy - induction chemotherapy - oxaliplatin - rectal cancer

Literatur

• 01 Aschele C, Pinto C, Cordio S et al.. Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer. Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial.  J Clin Oncol. 2009;  18. 804; CRA4008
• 02 Bengala C, Bettelli S, Bertolini F, Salvi S, Chiara S, Sonaglio C, Losi L, Bigiani N, Sartori G, Dealis C, Malavasi N, D'Amico R, Luppi G, Gatteschi B, Maiorana A, Conte P F. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.  Ann Oncol. 2009;  20 (3) 469-74
• 03 Blaszkowsky L S, Hong T S, Zhu A X, Kwak E L, Mamon H J, Shellito P C, Cusack J C, Berger D, Horgan K, Ryan D P. A phase I/II study of bevacizumab (beva), erlotinib (erl), and 5-fluorouracil (5-FU) with concurrent external beam radiation therapy (RT) in locally advanced rectal cancer.  LARC J Clin Oncol. 2009;  27. 15s (suppl; abstr 4106)
• 04 Bosset J F, Collette L, Calais G et al.. Chemotherapy with preoperative radiotherapy in rectal cancer.  N Engl J Med. 2006;  355. 1114–23
• 05 Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol; Mar.15.2010 [Epub ahead of print]
• 06 Capirci C, Valentini V, Cionini L et al.. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer. long-term analysis of 566 ypCR patients.  Int J Radiat Oncol Biol Phys. 2008;  72 (1) 99-107
• 07 Chua Y J, Barbachano Y, Cunningham D, Oates J R, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt N C, Chau I. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer. a phase 2 trial.  Lancet Oncol. 2010;  11 (3) 241-8
• 08 Collette L, Bosset J F, den Dulk M et al.. Patients with curative resection of cT3–4 rectal cancer after preoperative radiotherapy or radiochemotherapy. does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.  J Clin Oncol. 2007;  25 4339-4340
• 09 Crane C, Crane C H, Eng C, Feig B W, Das P, Skibber J M, Chang G J, Wolff R A, Krishnan S, Hamilton S, Janjan N A, Maru D M, Ellis L M, Rodriguez-Bigas M A. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.  Int J Radiat Oncol Biol Phys. 2010;  76 (3) 824-30
• 10 Czito B G, Bendell J C, Willett C G, Morse M A, Blobe G C, Tyler D S, Thomas J, Ludwig K A, Mantyh C R, Ashton J, Yu D, Hurwitz H I. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer. Phase I trial results.  Int J Radiat Oncol Biol Phys. 2007;  68 (2) 472-8
• 11 Debucquoy A, Haustermans K, Daemen A, Aydin S, Libbrecht L, Gevaert O, De Moor B, Tejpar S, McBride W H, Penninckx F, Scalliet P, Stroh C, Vlassak S, Sempoux C, Machiels J P. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer.  J Clin Oncol. 2009;  27 (17) 2751-7
• 12 Di Petrillo T, Pricolo V, Lagares-Garcia J, Sikov W, Vrees M, McNulty B, O'Connor B, Klipfel A, Khurshid H, Safran H. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation in clinical stage II-III rectal cancer.  J Clin Oncol. 2009;  27. 15s (suppl; abstr 4105)
• 13 Erben P, Ströbel P, Horisberger K, Popa J, Bohn B, Hanfstein B, Kähler G, Kienle P, Post S, Wenz F, Hochhaus A. Hofheinz R-D. KRAS & BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.  Int J Radiat Oncol Biol Phys. 2010;  [im Review]
• 14 Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, Vera R, Escudero P, Maurel J, Marcuello E, Mengual J L, Saigi E, Estevan R, Mira M, Polo S, Hernandez A, Gallen M, Arias F, Serra J, Alonso V. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer. Grupo cancer de recto 3 study.  J Clin Oncol. 2010;  28(5) 859-65
• 15 Gerard J P, Conroy T, Bonnetain F et al.. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers. results of FFCD 9203.  J Clin Oncol. 2006;  24 4620-5
• 16 Gerard J P, Azria D, Gourgou-Bourgade S et al.. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer. results of the phase III trial ACCORD 12/0405-Prodige 2.  J Clin Oncol. 2010;  28 1638-44
• 17 Glynne-Jones R, Grainger J, Harrison M, Ostler P, Makris A. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer. should we be more cautious?.  Br J Cancer. 2006;  94 (3) 363-71
• 18 Glynne-Jones R, Mawdsley S, Harrison M. Cetuximab and chemoradiation for rectal cancer – is the water getting muddy?. Acta Oncol; Feb.24.2010 [Epub ahead of print]
• 19 Guillem Guillem J G, Díaz-González J A, Minsky B D, Valentini V, Jeong S Y, Rodriguez-Bigas M A, Coco C, Leon R, Hernandez-Lizoain J L, Aristu J J, Riedel E R, Nitti D, Wong W D, Pucciarelli S. T3N0 rectal cancer. potential overtreatment with preoperative chemoradiotherapy is warranted.  J Clin Oncol. 2008;  26 (3) 368-73
• 20 Hofheinz R, Wenz F, Post S et al.. Capecitabine versus 5-fluorouracil-based (neo)adjuvant chemoradiotherapy for locally advanced rectal cancer. safety results of a randomized phase III trial.  J Clin Oncol. 2009;  18S:171S; 4014; 
• 21 Horisberger K, Treschl A, Mai S et al.. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer. results of a Phase II MARGIT trial.  Int J Radiat Oncol Biol Phys. 2009;  74 (5) 1487-93
• 22 Marijnen C A. Preoperative chemoradiotherapy regimen with capecitabine and bevacizumab in locally advanced rectal cancer. a feasibility study of the Dutch Coloretcal Cancer Group (DCCG).  J Clin Oncol. 2008;  26: (suppl; abstr 15040)
• 23 Marquardt F, Rödel F, Capalbo G, Weiss C, Rödel C. Molecular targeted treatment and radiation therapy for rectal cancer.  Strahlenther Onkol. 2009;  185(6) 371-8
• 24 Nogue M, Salud A, Vicente P, Pericay C, Arriví A, Roca J M, Losa F, Ponce J, Safont M J, Guasch I. Addition of bevacizumab to induction plus concomitant capecitabine-oxaliplatin (XELOX) chemoradiotherapy (CRT) in MRI poor prognosis locally advanced rectal cancer. Avacross study.  J Clin Oncol. 2009;  18S: 193S; 4100
• 25 Resch G, de Vries A, Öfner D, Eisterer W, Rabl H, Tschmelitsch J, Gnant M, Thaler J. Preoperative treatment with capecitabine (C), bevacizumab (B), and radiotherapy (RT) for primary locally advanced rectal cancer (LARC): A two-stage phase II clinical trial. ASCO GI Cancer Symposium; 2010 Abstract No. 496
• 26 Rödel C, Sauer R. Integration of novel agents into combined-modality treatment for rectal cancer patients.  Strahlenther Onkol. 2007;  183 227-235
• 27 Sauer R, Becker H, Hohenberger W et al.. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med; 2004. 351: 1731-1740
• 28 Schrag D, Weiser M R, Goodman K A, Reidy D L, Cercek A, Gonen M, Wong W D, Temple L K, Paty P, Saltz L. Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. ASCO GI Cancer Symposium; 2010 Abstract No. 434
• 29 Willett C G, Duda D G, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani D V, Lahdenranta J, Chung D C, Fischman A J, Lauwers G Y, Shellito P, Czito B G, Wong T Z, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen H X, Clark J W, Jain R K. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer. a multidisciplinary phase II study.  J Clin Oncol. 2009;  27 (18) 3020-6
• 30 Willett C G, Boucher Y, di Tomaso E, Duda D G, Munn L L, Tong R T, Chung D C, Sahani D V, Kalva S P, Kozin S V, Mino M, Cohen K S, Scadden D T, Hartford A C, Fischman A J, Clark J W, Ryan D P, Zhu A X, Blaszkowsky L S, Chen H X, Shellito P C, Lauwers G Y, Jain R K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.  Nat Med. 2004;  10 (2) 145-7

Korrespondenzadresse